tailieunhanh - Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Selective BRAF inhibitors, vemurafenib and dabrafenib, and the MEK inhibitor, trametinib, have been approved for treatment of metastatic melanomas with a BRAF mutation. The clinical significance of non-codon 600 mutations remains unclear, in part, due to variation of kinase activity for different mutants. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN